共 6 条
TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis
被引:0
|作者:
Shurygina, Anna-Polina S.
[1
]
Zabolotnykh, Natalia, V
[2
]
Vinogradova, Tatiana, I
[2
]
Vitovskaya, Maria L.
[2
]
Dogonadze, Marine Z.
[2
]
Vasilyev, Kirill A.
[1
]
Buzitskaya, Zhanna, V
[1
]
Yablonskiy, Petr K.
[2
]
Lioznov, Dmitriy A.
[1
]
Stukova, Marina A.
[1
]
机构:
[1] Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197022, Russia
[2] Minist Hlth Russian Federat, St Petersburg State Res Inst Phthisiopulmonol, St Petersburg 194064, Russia
关键词:
TB-specific immunotherapy;
mucosal vaccine;
drug-resistant tuberculosis;
influenza vector;
ESAT6;
T-CELLS;
LYMPHOID-TISSUE;
ESAT-6;
PROTEIN;
MEMORY;
D O I:
10.3390/pharmaceutics16070857
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The steady rise of drug-resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, we aimed to evaluate the potency of the mucosal vector vaccine TB/FLU-06E as part of a complex treatment regimen for drug-susceptible (DS) or drug-resistant (DR) tuberculosis in C57BL/6 mice. Incorporating TB/FLU-06E into the treatment protocol significantly increased the effectiveness of therapy for both forms of tuberculosis. It was evidenced by higher survival rates and reduced pulmonary bacterial load (1.83 lg CFU for DS tuberculosis and 0.93 lg CFU for DR tuberculosis). Furthermore, the treatment reduced pathomorphological lesions in the lungs and stimulated the local and systemic T-helper 1 (Th1) and cytotoxic T-lymphocyte (CTL) anti-TB immune responses. Thus, therapeutic immunization with the TB/FLU-06E vaccine significantly enhances the efficacy of tuberculosis treatment, which is particularly important in DR tuberculosis.
引用
收藏
页数:15
相关论文